Meet Our Team
Let our team of experts guide you with all of your practice needs.
Karen Duda PCMH CCE
The Verden Group
Business Development & Client Manager
PCS
Business Development & Client Manager
IPMSO
Business Development & Client Manager
Karen joined The Verden Group in 2016, bringing an extensive healthcare administration background to the team spanning front- and back-office operations, physician practice management, and executive assistance in hospital settings.
She has worked across our companies, in the role of operations at The Verden Group, as a Certified Content Expert (CCE) and consultant with Patient Centered Solutions, and now heads up Business Development and Client Services and is a partner at Independent Practice MSO.
Karen is based in Maryland where she resides with her husband, two children, and several furry family members.
Facebook Posts
Outsourcing chronic care management can have many benefits for small practices. Here are tips on how to successfully implement a CCM program that would be advantageous for both your practice and patients.
"Successfully implementing a CCM program starts with laying the operational groundwork: integrating new staff and installing healthIT software. Committing time and resources into integrating remote care managers early on is critical to reaping the benefits long term. By treating remote care coordinators as true extensions of your staff, adapting to the culture, tone, and workflow of your practice, they eventually become integral parts of practice operations, and in some cases, may even be willing to work in the office a few days a week to get additional face-to-face time with practice staff and patients. This frees up existing staff to manage other important tasks."
#physicians #doctors #pediatricians #pediatricpractice #physicianpractice #medicalpractice
How to successfully outsource chronic care management at a small practice
www.medicaleconomics.com
Pfizer reports positive results for COVID-19 vaccine in children. Read the latest here.
"Pfizer and COVID-19 vaccine development partner BioNTech reported Monday positive topline results from a pivotal trial of the vaccine in children aged 5 to 11 years. The vaccine was determined to be safe and well tolerated in the youngest age group yet to receive the 2-shot series, according to a Pfizer press statement.
Results of the phase 2/3 trial showed a robust neutralizing antibody response to the 2-dose regimen of 10 µg administered 21 days apart—a dose smaller than the 30-µg given to people aged ≥12 years. The antibody responses among the younger volunteers were comparable to that seen in trials of the vaccine in those aged 16 to 25 years, according to the company. Side effects, too, were comparable to those seen in the older cohort."
#pediatrics #pediatricians #pediatricpractice #covidvaccine #pfizer
Coronavirus Delta variant, vaccine, and case numbers in the United States: Sept. 21, 2021
www.medicaleconomics.com
The AAP has new recommendations for using consistent terminology to describe and classify unexpected and unexplained infant deaths.
"Throughout the years, many new terms have been used to classify infant deaths to reflect whether they are believed to be accidental or undetermined or fall under other categories," said Dr. Vincent J. Palusci, MD, MS, FAAP, a co-author of the report.
"This has led to inconsistencies in terms used, which in turn increases the chances of communication errors and misunderstandings. Our goal is to establish uniform and shared terminology so that we can best support families after their loss and work to prevent more deaths."
#pediatrics #pediatricians #pediatricpractice #sidsawareness
Defining Terminology for Unexpected, Unexplained Infant Deaths
www.healthychildren.org
Kenneth L. Fenchel